KDL(SH:603987) Sou Hu Cai Jing·2025-06-19 12:33Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kangdelai, a company in the medical device industry, which is currently underperforming compared to its peers [1][2] - As of June 19, Kangdelai's stock closed at 7.14 yuan, down 1.79%, with a rolling PE ratio of 14.47 times and a total market capitalization of 3.119 billion yuan [1] - The average PE ratio for the medical device industry is 48.08 times, with a median of 36.05 times, placing Kangdelai at the 34th position within the industry [1][2] Group 2 - As of March 31, 2025, Kangdelai has 25,817 shareholders, a decrease of 822 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Kangdelai includes the research, production, sales, and service of medical devices such as puncture needles and infusion devices, with various product categories [1] - The latest quarterly report for Q1 2025 shows Kangdelai achieved a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.7042 million yuan, with a gross profit margin of 32.02% [1]